ArticleCanadian Urological Association journal = Journal de l'Association des urologues du Canada2026
Predictors of successful erectile function using intracavernosal injection in post-prostatectomy men with erectile dysfunction.
Article in Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIntracavernosal injections (ICI) are commonly used to treat erectile dysfunction (ED) in men following radical prostatectomy (RP). Predictors of treatment success are still unclear. Our objective was to explore the relationship between various clinical and pathologic parameters and the achievement of satisfactory erections with ICI following RP.
methodsThis is a prospective study of men following RP with bilateral neurovascular bundle preservation who experienced ED refractory to treatment with phosphodiesterase type 5 inhibitors (PDE5I) at a minimum of six months after surgery. Three escalating dosages of TRIMIX were used consecutively (5 mg papaverine, 0.5 mg phentolamine, 10 mcg alprostadil; 10 mg papaverine, 1 mg phentolamine, 20 mcg alprostadil; 17 mg papaverine, 1 mg phentolamine, and 30 mcg alprostadil). Erection Hardness Scale (EHS) and International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) were used for functional assessments.
resultsThirty-four patients were stratified by their EHS scores and Trimix dosages: low-dose full responders (n=12), intermediate-dose full responders (n=10), high-dose partial responders (n=7), and high-dose failures (n=5). Twenty-nine patients (85%) reported on satisfactory erectile function with ICI. The ICIQ-SF scores were the only parameter that correlated significantly with successful erectile response, with median scores of 0, 3.5, 11, and 16 for the respective groups above (p=0.001). Univariate logistic regression demonstrated a significant association between ICIQ-SF scores and partial or non-response (odds ratio 1.3, 95% confidence interval 1.1-1.5, p=0.002).
conclusionsICI is an efficient therapy for achieving satisfactory erections following RP in PDE5I-resistant men. Sustainable urinary incontinence is a strong predictor of poor response to therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.